COPD-PH: statins improve SPAP, 6-minute walk distance in meta-analysis

  • Wang G & al.
  • Eur J Intern Med
  • 31 oct. 2019

  • de Miriam Davis, PhD
  • Clinical Essentials
El acceso al contenido completo es sólo para profesionales sanitarios registrados. El acceso al contenido completo es sólo para profesionales sanitarios registrados.

Takeaway

  • Statins improve systolic pulmonary artery pressure (SPAP) and 6-minute walk distance (6MWD) in patients with COPD plus pulmonary hypertension (COPD+PH) as a comorbidity, according to a small meta-analysis.

Why this matters

  • 5-year survival rate was only 36% in patients with COPD with a mean pulmonary artery pressure (mPAP) of >25 mm Hg vs 62% in patients with an mPAP of

Study design

  • Meta-analysis of 5 randomized controlled trails (RCTs; n=270) after a search of MEDLINE, Cochrane, ISI Web of Science, and Scopus.
  • Funding: None disclosed.

Key results

  • Statins reduced SPAP (weighted mean difference [WMD], −4.52 [95% CI, −6.32 to −2.72] mm Hg; I2=0%) relative to placebo.
  • Statins (vs placebo) increased 6MWD (WMD, 32.46 [95% CI, 13.63-51.29] m; I2=73%).
  • Statins (vs placebo) did not improve forced expiratory volume in 1 second (WMD, 2.58%; 95% CI, −4.89% to 10.05%; I2=0%).

Limitations

  • Small number of studies, participants.
  • No data on statin doses.